{"id":1068112,"date":"2021-02-06T08:51:03","date_gmt":"2021-02-06T13:51:03","guid":{"rendered":"https:\/\/www.immortalitymedicine.tv\/spero-therapeutics-provides-update-on-spr720-phase-2a-clinical-trial\/"},"modified":"2024-08-18T11:43:02","modified_gmt":"2024-08-18T15:43:02","slug":"spero-therapeutics-provides-update-on-spr720-phase-2a-clinical-trial","status":"publish","type":"post","link":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/global-news-feed\/spero-therapeutics-provides-update-on-spr720-phase-2a-clinical-trial.php","title":{"rendered":"Spero Therapeutics Provides Update on SPR720 Phase 2a Clinical Trial"},"content":{"rendered":"<p><![CDATA[CAMBRIDGE, Mass., Feb.  05, 2021  (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc.\u00a0(Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today announced that the United States Food and Drug Administration (FDA) informed Spero that a clinical hold has been placed on its Phase 2a clinical trial of SPR720, Spero\u2019s investigational oral antimicrobial agent being evaluated in patients with nontuberculous mycobacterial pulmonary disease (NTM-PD).]]><\/p>\n<p>Originally posted here:<br \/>\n<a target=\"_blank\" rel=\"nofollow noopener noreferrer\" href=\"http:\/\/www.globenewswire.com\/news-release\/2021\/02\/05\/2170670\/0\/en\/Spero-Therapeutics-Provides-Update-on-SPR720-Phase-2a-Clinical-Trial.html?f=22&amp;fvtc=5&amp;fvtv=46634288\" title=\"Spero Therapeutics Provides Update on SPR720 Phase 2a Clinical Trial\">Spero Therapeutics Provides Update on SPR720 Phase 2a Clinical Trial<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Originally posted here: Spero Therapeutics Provides Update on SPR720 Phase 2a Clinical Trial <a href=\"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/global-news-feed\/spero-therapeutics-provides-update-on-spr720-phase-2a-clinical-trial.php\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":64,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"limit_modified_date":"","last_modified_date":"","_lmt_disableupdate":"","_lmt_disable":"","footnotes":""},"categories":[1246886],"tags":[],"class_list":["post-1068112","post","type-post","status-publish","format-standard","hentry","category-global-news-feed"],"modified_by":null,"_links":{"self":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/1068112"}],"collection":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/users\/64"}],"replies":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/comments?post=1068112"}],"version-history":[{"count":0,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/1068112\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/media?parent=1068112"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/categories?post=1068112"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/tags?post=1068112"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}